Agricultural Applications of Cholestasis Treatment Technology
Legal Citation
Summary of the Inventive Concept
The present invention applies the core technology of cholestasis treatment to agricultural fields, enabling the prevention of crop yield loss, treatment of fungal infections, and improvement of soil fertility.
Background and Problem Solved
The original patent addressed the treatment of cholestatic diseases, specifically PBC and PSC. However, the present invention recognizes that the underlying principles of cholestasis treatment can be applied to agricultural fields, where soil health issues and fungal infections significantly impact crop yields. The new inventive concept addresses these limitations by providing a system for predicting crop yields, treating fungal infections, monitoring soil health, improving soil fertility, and optimizing irrigation systems.
Detailed Description of the Inventive Concept
The new claims describe a system for predicting crop yields by detecting changes in soil pH and applying a treatment composition to prevent cholestasis-induced yield loss. Another embodiment involves treating fungal infections in agricultural fields using a composition comprising elafibranor and a fungicide. The device for monitoring soil health detects changes in bile acid precursor C4 levels and alerts farmers to potential soil health issues. The method for improving soil fertility administers a composition comprising elafibranor and a nutrient supplement to promote healthy microbial growth and increase crop yields. Finally, the system for optimizing irrigation systems adjusts schedules to prevent waterlogged soil and promote healthy plant growth.
Novelty and Inventive Step
The new claims introduce a novel application of cholestasis treatment technology to agricultural fields, which is non-obvious compared to the original patent's focus on human diseases. The use of elafibranor in agricultural contexts and the integration of sensors and modules for monitoring and treating soil health issues are innovative and unanticipated.
Alternative Embodiments and Variations
Alternative embodiments may include using different sensors or modules, varying the composition of the treatment composition, or adapting the system for use in different types of agricultural fields or crops. Variations may also include integrating the inventive concept with existing agricultural technologies or practices.
Potential Commercial Applications and Market
The agricultural applications of cholestasis treatment technology have significant commercial potential in the agricultural industry, particularly in the areas of crop yield management, soil health monitoring, and fungal infection treatment. The target market includes farmers, agricultural companies, and organizations focused on sustainable agriculture.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K31/192 |
| A | A61 | A61K45/06 |
| A | A61 | A61P37/06 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical and agricultural biotechnology, with expertise in pharmacological compound applications, disease treatment methodologies, and agricultural biological interventions
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in biochemistry, pharmacology, or agricultural sciences, capable of understanding complex molecular interactions, drug repurposing strategies, and interdisciplinary technology transfer
Obviousness Rationale
A skilled practitioner would recognize the inherent potential for extending the molecular mechanisms of elafibranor beyond human cholestasis treatment to agricultural applications. The fundamental properties of the compound that interact with biological systems suggest predictable adaptations across different biological contexts. The PTD demonstrates a logical extension of the source patent's core technology by applying similar intervention strategies to soil and plant health management.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,523 |
|---|---|
| Title | Methods of treatment of cholestatic diseases |
| Assignee(s) | Genfit |